Preimplantation Genetic Testing Market to Reach US$999.2 Million by 2032, Says Persistence Market Research

The global Preimplantation Genetic Testing (PGT) Market has emerged as a critical component of modern reproductive medicine, reflecting the convergence of advanced genetics, precision diagnostics, and assisted reproductive technologies (ART). PGT enables genetic evaluation of embryos before implantation, helping identify chromosomal abnormalities or hereditary disorders, thereby improving the success rates of in vitro fertilization (IVF). This technology has revolutionized fertility care by empowering couples to make informed reproductive choices while reducing the likelihood of genetic diseases.

In 2025, the global PGT market is projected to reach a valuation of US$552.7 million, and it is anticipated to expand further to US$999.2 million by 2032, growing at a compound annual growth rate (CAGR) of 8.8%. The market's strong growth trajectory is driven by rising infertility rates, increasing maternal age, and growing awareness of genetic disorders. The increasing use of next-generation sequencing (NGS), improved embryo biopsy techniques, and the growing accessibility of IVF centers globally have further accelerated demand. North America dominates the global PGT market owing to its advanced IVF infrastructure, high awareness levels, and favorable healthcare investments, while Asia Pacific is witnessing the fastest growth due to expanding healthcare infrastructure, supportive policies, and increasing access to fertility care.

Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/34757

Key Highlights from the Report

• The global PGT market is valued at US$552.7 million in 2025, projected to reach US$999.2 million by 2032.
• Next-Generation Sequencing (NGS) leads the market due to superior accuracy and reliability.
• North America holds the largest regional share, driven by technological advancement and robust healthcare systems.
• Asia Pacific is the fastest-growing region owing to rising fertility treatments and healthcare investments.
• Increasing maternal age and infertility rates are major growth drivers.
• Integration of AI and personalized medicine offers emerging growth opportunities for PGT providers.

Market Segmentation
By Product Type

The preimplantation genetic testing market is segmented by product type into kits, reagents, instruments, and software solutions. Among these, kits dominate the market, primarily due to their simplicity, consistency, and compatibility with existing IVF laboratory setups. Pre-validated kits containing optimized reagents minimize human error, reduce testing complexity, and ensure high-quality results across fertility clinics. As IVF adoption continues to rise, fertility centers prefer standardized testing solutions to streamline workflows and improve efficiency. Moreover, the growing availability of cost-effective kits tailored for emerging markets is widening accessibility and accelerating market penetration.

By Technology

Next-Generation Sequencing (NGS) represents the leading technology segment in the PGT market. NGS enables comprehensive screening of embryos for chromosomal abnormalities and genetic mutations, offering superior resolution and accuracy compared to older techniques like fluorescence in situ hybridization (FISH) or polymerase chain reaction (PCR). The technology facilitates simultaneous assessment of multiple embryos, improving selection accuracy and IVF success rates. Furthermore, as sequencing costs decline and computational capabilities expand, NGS-based platforms are becoming the preferred choice for fertility centers globally. The growing integration of AI-driven data analysis tools within NGS platforms further enhances the predictive precision of genetic testing.

By Application

Within applications, aneuploidy testing accounts for the largest market share, representing approximately 41.0% of total revenue in 2024. This dominance is attributed to the high prevalence of chromosomal abnormalities, particularly among older women, and the need to minimize implantation failure or miscarriage risk. Aneuploidy testing allows fertility specialists to identify embryos with abnormal chromosome counts, improving pregnancy outcomes and reducing genetic risks. Moreover, technological advances such as high-throughput sequencing and automated interpretation systems are expanding the scope and adoption of aneuploidy testing in clinical settings.

By End User

The major end users of preimplantation genetic testing include fertility clinics, hospitals, and diagnostic laboratories. Fertility clinics hold the largest market share due to their role as primary providers of assisted reproductive technology services. These clinics have been early adopters of advanced genetic testing tools to enhance IVF success rates and improve patient outcomes. Hospitals are also increasing their use of PGT as part of comprehensive reproductive care programs, supported by improved reimbursement structures and specialized fertility units. Diagnostic laboratories, especially those with genomic expertise, are partnering with clinics to provide specialized testing services, thereby expanding access to precision fertility care.

Read Detailed Analysis: https://www.persistencemarketresearch.com/market-research/preimplantation-genetic-testing-market.asp

Regional Insights

North America

North America remains the global leader in the preimplantation genetic testing market, primarily driven by its advanced healthcare infrastructure, extensive availability of fertility clinics, and high awareness of genetic disorders. The United States contributes the largest share, supported by favorable reimbursement policies, continuous innovation in IVF techniques, and a robust network of diagnostic laboratories. Additionally, strategic collaborations between biotech firms, academic institutions, and healthcare providers are accelerating product innovation and adoption. Rising maternal age and growing demand for safe, efficient ART solutions are further propelling regional growth.

Europe

The European PGT market is experiencing consistent growth fueled by the increasing acceptance of IVF and a heightened focus on genetic screening. The region benefits from favorable regulatory frameworks that ensure ethical and clinical safety in PGT implementation. Countries such as the United Kingdom, Germany, and France are at the forefront, leveraging advanced NGS technologies to improve diagnostic precision. The UK is expected to witness the fastest growth between 2025 and 2032 due to growing public awareness, a supportive healthcare environment, and an expanding network of fertility clinics. The integration of data-driven genomic analysis is further enhancing Europe's clinical outcomes and reinforcing its competitive market position.

Asia Pacific

Asia Pacific is the fastest-growing regional market for preimplantation genetic testing, driven by rising infertility rates, increasing public awareness, and improving access to fertility care. Rapid urbanization, delayed childbearing, and supportive government initiatives are expanding the market across countries such as China, India, and Japan. The region is also witnessing growing investment in genomics research and the emergence of local manufacturers offering affordable testing kits and reagents. As social acceptance of assisted reproductive technologies increases, Asia Pacific is poised to become a major hub for PGT innovation and service expansion in the coming decade.

Market Drivers

The preimplantation genetic testing market's growth is strongly influenced by several interconnected drivers. A primary factor is the rising maternal age, which directly correlates with increased infertility and chromosomal abnormalities in embryos. More couples are turning to assisted reproductive technologies such as IVF, where PGT plays a vital role in improving pregnancy outcomes. The prevalence of genetic disorders, including cystic fibrosis, thalassemia, and Down syndrome, has further underscored the importance of early genetic screening.

Technological advancements, particularly in next-generation sequencing (NGS) and AI-assisted embryo selection, have enhanced the precision and efficiency of testing procedures. These innovations enable comprehensive embryo profiling with higher accuracy and reduced turnaround time. Furthermore, increasing awareness of reproductive health, growing healthcare expenditure, and supportive government policies in developed economies are strengthening market demand. Collectively, these drivers are shaping a dynamic landscape where PGT is becoming a mainstream component of fertility care.

Market Restraints

Despite its strong growth potential, the PGT market faces several challenges that constrain its broader adoption. One of the foremost concerns involves the clinical risks associated with embryo biopsy, where the extraction of cells may occasionally cause embryo damage, potentially affecting implantation outcomes. Although advanced biopsy techniques have improved safety, some studies suggest higher risks of complications such as preeclampsia and preterm birth.

Another critical restraint lies in diagnostic limitations and false positives, which can lead to discarding viable embryos. The issue of mosaicism-where embryos contain both normal and abnormal cells-complicates accurate diagnosis. Ethical and legal considerations also restrict PGT in certain regions due to concerns over embryo selection and potential misuse. Notably, legal disputes such as the Monash IVF class-action case in Australia, involving alleged misclassification errors, have highlighted the need for improved accuracy and regulation. These challenges underscore the necessity for stringent clinical standards, transparent counseling, and continuous technological refinement to ensure patient safety and trust.

Market Opportunities

The future of the PGT market is shaped by expanding technological frontiers and evolving clinical applications. One of the most promising opportunities lies in technological advancements in genetic analysis, particularly through next-generation sequencing and artificial intelligence. NGS offers high-resolution screening, while AI models-such as convolutional neural networks-can predict embryo viability with remarkable accuracy.

Emerging non-invasive PGT (niPGT) techniques that utilize cell-free DNA from embryo culture media represent another major opportunity. These methods eliminate the need for embryo biopsy, reducing clinical risks and costs while maintaining diagnostic reliability. The growing integration of PGT with personalized medicine and precision reproductive care further opens new avenues for targeted genetic interventions. Expanding fertility tourism in emerging markets, coupled with increased investment in genomic research, will likely propel innovation and market growth over the coming years.

Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/34757

Company Insights

The preimplantation genetic testing market is characterized by intense competition, with leading players focusing on innovation, strategic collaborations, and expansion into high-growth regions. Major companies operating in this market include:

• Thermo Fisher Scientific, Inc.
• Cooper Surgical, Inc.
• Illumina, Inc.
• Abbott Laboratories
• Agilent Technologies, Inc.
• Medicover Genetics
• Revvity Inc.
• Takara Bio Inc.
• Genea Biomedx
• SeraCare Life Sciences
• Shiva Scientific Company
• Others

Market Segmentation

By Product

Kits
Reagents and Consumables

By Technology

Next-Generation Sequencing
Fluorescence In Situ Hybridization
Polymerase Chain Reaction
Single-Nucleotide Polymorphism

Comparative Genomic Hybridization

By Application

Aneuploidy
X-Linked Disorders
Structural Chromosomal Abnormalities
Single Gene Disorders
Gender Identification
HLA Typing for Stem Cell Transplants

By Distribution Channel

Hospitals
Fertility Clinics
Diagnostic Laboratories
Academic & Research Institutions
Others

By Region

North America
Europe
East Asia
South Asia and Oceania
Latin America
Middle East and Africa

Recent Developments

In February 2025, Thermo Fisher Scientific Inc. announced the acquisition of Solventum's Purification & Filtration business for approximately $4.1 billion, strengthening its bioproduction capabilities and expanding its genetic testing portfolio.

In January 2025, Illumina, Inc. introduced significant upgrades to its NovaSeq X Series, featuring enhanced software, reagent kits, and single-flow-cell systems to boost sequencing speed and accuracy, reaffirming its leadership in genomic solutions.

These developments demonstrate a broader industry shift toward high-throughput, AI-integrated, and user-friendly genetic testing systems that meet the growing clinical demand for accuracy and efficiency.

Conclusion

The global Preimplantation Genetic Testing Market is entering a transformative phase characterized by technological innovation, rising global awareness of reproductive health, and expanding accessibility to fertility care. As genetic analysis becomes increasingly precise, and ethical frameworks strengthen clinical governance, PGT is poised to become an integral part of reproductive medicine worldwide.

Despite existing restraints, including ethical complexities and diagnostic challenges, the long-term outlook remains highly optimistic. The synergy between next-generation sequencing, artificial intelligence, and non-invasive diagnostic techniques is expected to redefine the fertility landscape. With North America maintaining leadership and Asia Pacific rapidly emerging as a growth frontier, the global PGT market is set to nearly double in value by 2032-reaching close to US$1 billion. The continued collaboration between biotechnology firms, fertility clinics, and research institutions will play a pivotal role in shaping the future of genetic testing in reproductive healthcare, ensuring healthier generations and improved fertility outcomes.

Read More Related Reports:

Anti-venom Market https://www.persistencemarketresearch.com/market-research/anti-venom-market.asp
Medical Simulation Market https://www.persistencemarketresearch.com/market-research/medical-simulation-market.asp
Polyclonal Antibody Market https://www.persistencemarketresearch.com/market-research/polyclonal-antibody-market.asp
Lateral Flow Assay Market https://www.persistencemarketresearch.com/market-research/lateral-flow-assays-market.asp
Non-injectable Insulin Market https://www.persistencemarketresearch.com/market-research/non-injectable-insulin-market.asp

Contact Us:

Persistence Market Research
Second Floor, 150 Fleet Street, London, EC4A 2DQ, United Kingdom
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.